CardioVascular Dynamics names Dr. Hal Heitzmann as V.P., R&D Engineering.IRVINE, Calif.--(BW HealthWire)--March 5, 1997--CardioVascular Dynamics Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :CCVD CCVD Communauté de Communes du Val de Drôme CCVD Combustion Chemical Vapor Deposition ) Wednesday announced that Dr. Hal Heitzmann has joined the company as vice president of research, development and engineering. Heitzmann, a Ph.D. graduate in molecular biophysics This article or section needs sources or references that appear in reliable, third-party publications. Alone, primary sources and sources affiliated with the subject of this article are not sufficient for an accurate encyclopedia article. and biochemistry from Yale University, will be responsible for all CVD CVD Cardiovascular disease, see there new product research and development activities. Heitzmann has over twenty years TWENTY YEARS. The lapse of twenty years raises a presumption of certain facts, and after such a time, the party against whom the presumption has been raised, will be required to prove a negative to establish his rights. 2. of experience in new product engineering in the medical device arena, including nearly ten years at Baxter International Inc. Most recently, Heitzmann was vice president of catheter development at Cardiac Pathways Corp. Commenting on Heitzmann's appointment, Michael Henson, CVD chairman and chief executive officer, said, "CVD currently has a large number of new catheters, cardiovascular stent devices and vascular access vascular access Clinical medicine The ability to enter the vascular system; the ease with which the vascular system can be entered for administering therapy or obtaining blood for testing products in various stages of development. We are pleased to have an individual with the experience and qualifications as Dr. Heitzmann join CVD to help bring these products to market." CVD develops and markets site-specific drug delivery catheters, coronary and vascular stent devices, stent delivery systems and vascular access products. -0- Note: Except for the historical information contained herein, the matters discussed in this news release may be forward-looking statements, the accuracy of which is necessarily subject to risks and uncertainties. The receipt of regulatory approvals and clinical efficacy of, manufacturability of and market demand for products, among other matters discussed in this release, may cause actual results to differ significantly from the discussion of such matters in the forward-looking statements. Actual results may be affected by, among other things, risk and uncertainties related to new product development and introduction cycles, research and development activities, delays by regulatory authorities, scientific advances by CVD or third parties, introduction of competitive products, third party reimbursement and physician training, as well as those factors set forth in the CVD prospectus, dated June 19, 1996. CONTACT: CVD, Irvine Heather Murray Investor Relations Investor relations The process by which the corporation communicates with its investors. 714/457-9546 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion